Is Monopar Therapeutics (MNPR) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 15.6% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 15.6% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 0.0% / 33% | 99.9% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 15.6% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 0.0% / 33% | 99.9% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -14.2% | |
| Return on Assets (ROA) | -10.4% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$6M |
| Free Cash Flow | -$6M |
| Debt-to-Equity | 0.1 |
| Current Ratio | 51.4 |
| Total Assets | $60M |
Price & Trading
| Last Close | $54.56 |
| 50-Day MA | $59.89 |
| 200-Day MA | $60.52 |
| Avg Volume | 275K |
|
52-Week Range
$26.05
| |
About Monopar Therapeutics (MNPR)
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Monopar Therapeutics (MNPR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Monopar Therapeutics is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Monopar Therapeutics's debt ratio?
Monopar Therapeutics's debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Monopar Therapeutics's key financial metrics?
Monopar Therapeutics has a market capitalization of $362M. Return on equity stands at -14.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.